{"zip": "201203", "sector": "Healthcare", "fullTimeEmployees": 2453, "longBusinessSummary": "Shanghai Junshi Biosciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in the therapeutic areas of oncology, metabolic, auto-immunity, neurologic, and infectious diseases in the People's Republic of China. The company offers JS001, a recombinant humanized anti-PD-1 monoclonal antibody under the trade name of TUOYIR for the indication of melanoma, mucosal melanoma, soft tissue sarcoma, nasopharyngeal carcinoma, urothelial carcinoma, non-small cell lung carcinoma, triple negative breast carcinoma, esophageal squamous cell carcinoma, and hepatocellular carcinoma. It is also developing UBP1211, a biosimilar of Humira for the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriasis arthritis; JS002, a recombinant humanized anti-PCSK9 monoclonal antibody for treating hyperlipidemia; UBP1213, a recombinant humanized anti-BLyS monoclonal antibody for injection. In addition, the company is developing JS501, a biosimilar of Avastin; and JS003, a recombinant humanized anti-PD-L1 monoclonal antibody for injection; JS101, a pan-CDK inhibitor; TAB004/JS004, a recombinant humanized anti-BTLA monoclonal antibody for injection; and JS005, a recombinant humanized anti-IL-17A monoclonal antibody for injection. It has an agreement with Eli Lilly and Company to co-develop therapeutic antibodies for the potential prevention and treatment of COVID-19, the disease caused by the SARS-CoV-2 novel coronavirus; collaboration with Merck & Co., Inc. to explore new combination treatment for head and neck cancer patients, as well as Coherus Biosciences, Inc. for the development and commercialization of toripalimab, Junshi Biosciences' anti-PD-1 antibody; and a research collaboration and license agreement with Revitope Oncology Inc to explore immunotherapies with precision-targeted T-cell engaging antibodies. The company was founded in 2012 and is headquartered in Shanghai, People's Republic of China.", "city": "Shanghai", "phone": "86 21 6105 8800", "country": "China", "companyOfficers": [], "website": "http://www.junshipharma.com", "maxAge": 1, "address1": "Building 2", "fax": "86 21 8016 4691", "industry": "Biotechnology", "address2": "13th Floor Nos. 36 and 58, Hai Qu Road Pilot Free Trade Zone", "ebitdaMargins": -0.29446, "profitMargins": -0.34955, "grossMargins": 0.78963995, "operatingCashflow": -703262784, "revenueGrowth": 8.388, "operatingMargins": -0.33909, "ebitda": -894559232, "targetLowPrice": null, "recommendationKey": "none", "grossProfits": 1218138119, "freeCashflow": -1318918528, "targetMedianPrice": null, "currentPrice": 47.35, "earningsGrowth": null, "currentRatio": 3.134, "returnOnAssets": -0.096269995, "numberOfAnalystOpinions": null, "targetMeanPrice": null, "debtToEquity": 14.004, "returnOnEquity": -0.22994, "targetHighPrice": null, "totalCash": 3282303232, "totalDebt": 876460736, "totalRevenue": 3037972992, "totalCashPerShare": 3.762, "financialCurrency": "CNY", "revenuePerShare": 3.601, "quickRatio": 2.647, "recommendationMean": null, "exchange": "SHH", "shortName": "SHANGHAI JUNSHI BIOSCIENCES CO ", "longName": "Shanghai Junshi Biosciences Co., Ltd.", "exchangeTimezoneName": "Asia/Shanghai", "exchangeTimezoneShortName": "CST", "isEsgPopulated": false, "gmtOffSetMilliseconds": "28800000", "underlyingSymbol": null, "quoteType": "EQUITY", "symbol": "688180.SS", "underlyingExchangeSymbol": null, "headSymbol": null, "messageBoardId": "finmb_309250670", "uuid": "80d1a131-81a5-3389-aab7-9a1ef3f9fee8", "market": "cn_market", "annualHoldingsTurnover": null, "enterpriseToRevenue": 16.569, "beta3Year": null, "enterpriseToEbitda": -56.27, "52WeekChange": null, "morningStarRiskRating": null, "forwardEps": null, "revenueQuarterlyGrowth": null, "sharesOutstanding": 691460992, "fundInceptionDate": null, "annualReportExpenseRatio": null, "totalAssets": null, "bookValue": 7.173, "sharesShort": null, "sharesPercentSharesOut": null, "fundFamily": null, "lastFiscalYearEnd": 1609372800, "heldPercentInstitutions": 0.0127799995, "netIncomeToCommon": -1061926848, "trailingEps": -1.259, "lastDividendValue": null, "SandP52WeekChange": null, "priceToBook": 6.601143, "heldPercentInsiders": 0, "nextFiscalYearEnd": 1672444800, "yield": null, "mostRecentQuarter": 1617148800, "shortRatio": null, "sharesShortPreviousMonthDate": null, "floatShares": 562114273, "beta": -0.081467, "enterpriseValue": 50336538624, "priceHint": 2, "threeYearAverageReturn": null, "lastSplitDate": null, "lastSplitFactor": null, "legalType": null, "morningStarOverallRating": null, "earningsQuarterlyGrowth": null, "priceToSalesTrailing12Months": 12.721941, "dateShortInterest": null, "pegRatio": null, "ytdReturn": null, "forwardPE": null, "lastCapGain": null, "shortPercentOfFloat": null, "sharesShortPriorMonth": null, "category": null, "fiveYearAverageReturn": null, "previousClose": 47.63, "regularMarketOpen": 47.89, "twoHundredDayAverage": 69.53831, "trailingAnnualDividendYield": null, "payoutRatio": 0, "volume24Hr": null, "regularMarketDayHigh": 47.98, "navPrice": null, "averageDailyVolume10Day": 3214991, "regularMarketPreviousClose": 47.63, "fiftyDayAverage": 53.605278, "trailingAnnualDividendRate": null, "open": 47.89, "averageVolume10days": 3214991, "expireDate": null, "algorithm": null, "dividendRate": null, "exDividendDate": null, "circulatingSupply": null, "startDate": null, "regularMarketDayLow": 47.04, "currency": "CNY", "regularMarketVolume": 2044673, "lastMarket": null, "maxSupply": null, "openInterest": null, "marketCap": 38648913920, "volumeAllCurrencies": null, "strikePrice": null, "averageVolume": 3870478, "dayLow": 47.04, "ask": 47.35, "askSize": null, "volume": 2044673, "fiftyTwoWeekHigh": 106.98, "fromCurrency": null, "fiveYearAvgDividendYield": null, "fiftyTwoWeekLow": 46.2, "bid": 47.34, "tradeable": false, "dividendYield": null, "bidSize": null, "dayHigh": 47.98, "regularMarketPrice": 47.35, "preMarketPrice": null, "logo_url": "https://logo.clearbit.com/junshipharma.com"}